News Ipsen to buy rare disease firm Clementia for up to $1.31bn France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
Digital Asking the right questions around AI, with Brian Alexander, ... At BIO 2025, editor-in-chief Jonah Comstock spoke with Brian Alexander, CEO of Valo Health, about how he’s seeing the AI conversation evolve.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face